calling all creatives

Houston entrepreneur creates a new digital platform to help connect freelancers to clients

Houston — much like the rest of the world — has a growing freelance economy. A local innovator has created a platform for freelancers to find work. Photo courtesy of Common Desk

By 2027, freelancers will account for the majority of the American workforce — and Houston is already well represented by the freelance space.

According to a recent study, Houston is home to 117,260 skilled freelancers who generated more than $4.1 billion in revenue in 2018. This burgeoning environment for freelancers presents many opportunities for innovations in the tech world, as one Houston entrepreneur has already discovered.

Yared Akalou, founder-and-CEO of Alcove Group and self-described designer-focused entrepreneur, released his third innovation catering to freelancers of the Houston area. His digital solutions platform, IAmOther50, assists freelancers with securing new clients by sharing their personal stories rather than just submitting their professional experience, it uses videos and articles to promote the work of a freelancer and connect them to their next client.

"I am really on a mission," Akalou tells InnovationMap. "I have been talking about the future of work for over a decade now. The paradigm will change to viewing work as a service, so it is important to tell a freelancer's story through a more engaging and novel way."

At first glance, the digital platform seems like a departure for Akalou who in 2017 founded Alcove, a portable laptop case that serves as a private workspace for freelancers to use amid coffee shops or coworking spaces. However, IAmOther50 serves as a distinctly separate yet integral part of his innovation landscape.

"These projects have been a combination of my focus and research," says Akalou. "My new platform works hand in hand with Alcove, supporting the mission to help people stay productive from anywhere."

The digital platform serves to capture the brand of the freelancer along with their personality and experience. It lives at the intersection of popular social media platforms and professional platforms such as LinkedIn, except just for freelancers in the Houston area. Currently, any freelancing professional in the Houston area can join for free by filling out a survey that customizes their goals for their profile.

"IAmOther50 provides information in a contextual way," says Akalou. "We have this guiding principle of delivering value even before the prospective client contacts the freelancer for an interview or potential position. It's about going beyond just a resume of what you've done and showcasing how you add value right now."

Akalou, who is also one of the mentors in The Ion Smart and Resilient Cities Accelerator, is focused on elevating the professional profiles of many freelancers, including those outside the Houston area. He is aiming to grow the platform to a self-service platform that can connect freelancers to clients all over the biggest metropolitan areas soon.


Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News